{"id":"https://openalex.org/W7224374213","doi":"https://doi.org/10.1186/s12883-026-05552-7","title":"Real-world treatment patterns of galcanezumab versus traditional oral migraine preventives: 12-month results from the TRIUMPH study","display_name":"Real-world treatment patterns of galcanezumab versus traditional oral migraine preventives: 12-month results from the TRIUMPH study","publication_year":2026,"publication_date":"2026-10-29","ids":{"openalex":"https://openalex.org/W7224374213","doi":"https://doi.org/10.1186/s12883-026-05552-7"},"language":"en","primary_location":{"id":"doi:10.1186/s12883-026-05552-7","doi":"https://doi.org/10.1186/s12883-026-05552-7","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12883-026-05552-7","pdf_url":null,"source":{"id":"https://openalex.org/S120289491","display_name":"BMC Neurology","issn_l":"1471-2377","issn":["1471-2377"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1186/s12883-026-05552-7","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073009086","display_name":"Sait Ashina","orcid":"https://orcid.org/0000-0003-3973-6640","observed_orcids":["https://orcid.org/0000-0003-3973-6640"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sait Ashina","raw_affiliation_strings":["Department of Neurology, and Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA"],"raw_orcid":"https://orcid.org/0000-0003-3973-6640","affiliations":[{"raw_affiliation_string":"Department of Neurology, and Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016058429","display_name":"Manjit Singh Matharu","orcid":"https://orcid.org/0000-0002-4960-2294","observed_orcids":["https://orcid.org/0000-0002-4960-2294"]},"institutions":[{"id":"https://openalex.org/I4210151618","display_name":"National Hospital for Neurology and Neurosurgery","ror":"https://ror.org/048b34d51","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1340918713","https://openalex.org/I4210151618"]},{"id":"https://openalex.org/I4405260083","display_name":"UCL Queen Square Institute of Neurology","ror":"https://ror.org/0370htr03","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I4405260083","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Manjit Matharu","raw_affiliation_strings":["Headache and Facial Pain Group, Queen Square Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK"],"raw_orcid":"https://orcid.org/0000-0002-4960-2294","affiliations":[{"raw_affiliation_string":"Headache and Facial Pain Group, Queen Square Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK","institution_ids":["https://openalex.org/I4210151618","https://openalex.org/I4405260083"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005207942","display_name":"Fumihiko Sakai","orcid":"https://orcid.org/0000-0001-9385-7991","observed_orcids":["https://orcid.org/0000-0001-9385-7991"]},"institutions":[{"id":"https://openalex.org/I4405284397","display_name":"Saitama Neuropsychiatric Institute","ror":"https://ror.org/03ft4zt70","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4405284397"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Fumihiko Sakai","raw_affiliation_strings":["Saitama Neuropsychiatric Institute, Saitama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saitama Neuropsychiatric Institute, Saitama, Japan","institution_ids":["https://openalex.org/I4405284397"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072739072","display_name":"Maurice Borges Vincent","orcid":"https://orcid.org/0000-0001-5855-6069","observed_orcids":["https://orcid.org/0000-0001-5855-6069"]},"institutions":[{"id":"https://openalex.org/I122140584","display_name":"Universidade Federal do Rio de Janeiro","ror":"https://ror.org/03490as77","country_code":"BR","type":"education","lineage":["https://openalex.org/I122140584"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Maurice Vincent","raw_affiliation_strings":["Department of Neurology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil"],"raw_orcid":"https://orcid.org/0000-0001-5855-6069","affiliations":[{"raw_affiliation_string":"Department of Neurology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil","institution_ids":["https://openalex.org/I122140584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090431664","display_name":"Lars Viktrup","orcid":"https://orcid.org/0000-0002-8739-0544","observed_orcids":["https://orcid.org/0000-0002-8739-0544"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lars Viktrup","raw_affiliation_strings":["Lilly Research Lab, Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":"https://orcid.org/0000-0002-8739-0544","affiliations":[{"raw_affiliation_string":"Lilly Research Lab, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089246132","display_name":"Georgia Martimianaki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Georgia Martimianaki","raw_affiliation_strings":["Lilly Research Lab, Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Lab, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071285179","display_name":"Rebecca L. Robinson","orcid":"https://orcid.org/0000-0003-1490-0491","observed_orcids":["https://orcid.org/0000-0003-1490-0491"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Rebecca L. Robinson","raw_affiliation_strings":["Lilly Research Lab, Eli Lilly and Company, Indianapolis, IN, USA"],"raw_orcid":"https://orcid.org/0000-0003-1490-0491","affiliations":[{"raw_affiliation_string":"Lilly Research Lab, Eli Lilly and Company, Indianapolis, IN, USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5071285179"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":{"value":3090,"currency":"USD","value_usd":3090},"apc_paid":{"value":3090,"currency":"USD","value_usd":3090},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.84695997,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10420","display_name":"Intracranial Aneurysms: Treatment and Complications","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10852","display_name":"Temporomandibular Joint Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3603","display_name":"Complementary and Manual Therapy"},"field":{"id":"https://openalex.org/fields/36","display_name":"Health Professions"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/galcanezumab","display_name":"galcanezumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/migraine-prevention","display_name":"migraine prophylaxis","score":0.8659999966621399},{"id":"https://openalex.org/keywords/anti-cgrp-monoclonal-antibodies","display_name":"CGRP monoclonal antibodies","score":0.8360000252723694},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.9440000057220459},{"id":"https://openalex.org/keywords/treatment-switching","display_name":"treatment switching","score":0.5659999847412109},{"id":"https://openalex.org/keywords/chronic-migraine","display_name":"chronic migraine","score":0.718999981880188},{"id":"https://openalex.org/keywords/treatment-refractoriness","display_name":"treatment refractoriness","score":0.7059999704360962},{"id":"https://openalex.org/keywords/acute-medication-use","display_name":"acute medication use","score":0.7250000238418579},{"id":"https://openalex.org/keywords/real-world-treatment-patterns","display_name":"real-world treatment patterns","score":0.7689999938011169},{"id":"https://openalex.org/keywords/drug-intolerance","display_name":"drug intolerance","score":0.32899999618530273},{"id":"https://openalex.org/keywords/drug-unavailability","display_name":"drug unavailability","score":0.5590000152587891},{"id":"https://openalex.org/keywords/time-to-treatment-discontinuation","display_name":"time to treatment discontinuation","score":0.5839999914169312},{"id":"https://openalex.org/keywords/time-to-treatment","display_name":"time to treatment","score":0.3179999887943268}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9395999908447266},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.9372000098228455},{"id":"https://openalex.org/C2778541695","wikidata":"https://www.wikidata.org/wiki/Q133823","display_name":"Migraine","level":2,"score":0.76910001039505},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.7141000032424927},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5737000107765198},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5386000275611877},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.5238000154495239},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.5005000233650208},{"id":"https://openalex.org/C163170386","wikidata":"https://www.wikidata.org/wiki/Q419432","display_name":"Calcitonin gene-related peptide","level":4,"score":0.4993000030517578},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.43799999356269836},{"id":"https://openalex.org/C2910587157","wikidata":"https://www.wikidata.org/wiki/Q133823","display_name":"Chronic Migraine","level":3,"score":0.3700000047683716},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.3691999912261963},{"id":"https://openalex.org/C12770488","wikidata":"https://www.wikidata.org/wiki/Q188449","display_name":"Neurosurgery","level":2,"score":0.31150001287460327},{"id":"https://openalex.org/C16568411","wikidata":"https://www.wikidata.org/wiki/Q83042","display_name":"Neurology","level":2,"score":0.2831999957561493},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.27799999713897705},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.2702000141143799},{"id":"https://openalex.org/C107130276","wikidata":"https://www.wikidata.org/wiki/Q133805","display_name":"Epidemiology","level":2,"score":0.2563999891281128}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1186/s12883-026-05552-7","doi":"https://doi.org/10.1186/s12883-026-05552-7","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12883-026-05552-7","pdf_url":null,"source":{"id":"https://openalex.org/S120289491","display_name":"BMC Neurology","issn_l":"1471-2377","issn":["1471-2377"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Neurology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1186/s12883-026-05552-7","doi":"https://doi.org/10.1186/s12883-026-05552-7","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s12883-026-05552-7","pdf_url":null,"source":{"id":"https://openalex.org/S120289491","display_name":"BMC Neurology","issn_l":"1471-2377","issn":["1471-2377"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMC Neurology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7156997967","https://openalex.org/W4414616075","https://openalex.org/W4220921685","https://openalex.org/W7155154161","https://openalex.org/W7155176106","https://openalex.org/W4391683855","https://openalex.org/W4393269240","https://openalex.org/W3154831305","https://openalex.org/W4387677010","https://openalex.org/W4393006084"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"This":[2,33],"study":[3,49],"describes":[4],"12-month":[5],"treatment":[6,51,79,166,173],"patterns":[7],"in":[8,45,132,147,161,178,181,229,240,332,344,349],"patients":[9,131,146,350],"with":[10,159,280,325,377],"migraine":[11,28,140,232],"who":[12],"initiated/switched":[13],"to":[14,78,208,248,312,336,352,355],"galcanezumab":[15],"(GMB),":[16],"a":[17,341],"calcitonin":[18],"gene-related":[19],"peptide":[20],"monoclonal":[21],"antibody":[22],"(CGRP":[23],"mAb),":[24],"or":[25,64,74],"traditional":[26],"oral":[27],"preventive":[29,156,327],"(TOMP)":[30],"medications.":[31],"Methods":[32],"multi-country,":[34],"prospective,":[35],"real-world,":[36],"observational,":[37],"TRIUMPH":[38],"(TReatment":[39],"of":[40,70,130,145,231,283,307,322,371],"mIgraine:":[41],"oUtcoMes":[42],"for":[43,62,184,205,373],"Patients":[44],"real-world":[46,319],"Healthcare":[47],"systems)":[48],"assessed":[50],"patterns,":[52],"index":[53],"drug":[54,72,75],"discontinuation,":[55],"and":[56,86,91,111,121,128,134,192,211,218,243,263,277,287,301,323,375],"acute":[57,237,347],"medication":[58,238,348],"use.":[59],"\u201cNegative":[60],"reasons\u201d":[61],"discontinuation":[63,80,174,206,321],"switch":[65],"were":[66,96,176,214,273,329],"defined":[67],"as":[68],"lack":[69],"efficacy,":[71],"intolerability":[73],"unavailability.":[76],"Time":[77],"was":[81,340,361],"estimated":[82],"using":[83,98,236],"Kaplan-Meier":[84],"methods":[85],"log-rank":[87],"test.":[88],"Hazard":[89],"ratios":[90,202],"confidence":[92],"intervals":[93],"(95%":[94,203],"CI)":[95,204],"determined":[97],"weighted":[99,200,226],"Cox":[100],"proportional":[101],"hazards":[102],"models.":[103],"Results":[104],"Among":[105],"2486":[106],"patients,":[107],"973":[108],"received":[109,113],"GMB":[110,133,149,179,242,276,294,333,353],"1138":[112],"TOMP":[114,135,162,182,244,278,313,337],"(mean":[115],"[standard":[116],"deviation]":[117],"age:":[118],"45.2":[119],"[13.6]":[120],"40.4":[122],"[13.2]":[123],"years,":[124],"respectively).":[125],"Approximately":[126],"70.0%":[127],"59.8%":[129],"cohorts,":[136,279],"respectively,":[137],"had":[138,151,296],"chronic":[139],"at":[141,168,367],"baseline.":[142,169],"Approximately,":[143],"37.3%":[144],"the":[148,368,378],"cohort":[150,183,295,334],"used":[152,304],"\u2265":[153],"3":[154,249],"prior":[155],"medications":[157,328],"compared":[158,311,335,354],"4.5%":[160],"cohort,":[163],"reflecting":[164],"greater":[165],"refractoriness":[167],"At":[170],"12":[171,264],"months,":[172,291],"rates":[175,272],"lower":[177],"than":[180],"negative":[185,209],"reasons":[186,210,213],"(12.7%":[187],"versus":[188,195,252,259,267],"17.4%;":[189],"P":[190,197,222,254,261,269],"=0.0022)":[191],"all-causes":[193],"(17.8%":[194],"23.2%;":[196],"=0.0025).":[198],"The":[199,225,359],"hazard":[201],"due":[207],"all-cause":[212],"0.53":[215],"(0.41,":[216],"0.68)":[217],"0.57":[219],"(0.46,":[220],"0.70),":[221],"<0.0001,":[223],"respectively.":[224,292],"mean":[227,281],"change":[228],"number":[230],"headache":[233],"days":[234],"(MHDs)":[235],"declined":[239],"both":[241],"cohorts":[245],"from":[246],"baseline":[247],"months":[250,257,265],"(-5.1":[251,258],"-3.4;":[253],"<0.0001),":[255],"6":[256],"-4.2;":[260],"=0.0234),":[262],"(-5.3":[266],"-4.3;":[268],"=0.0168).":[270],"Persistence":[271],"similar":[274],"between":[275],"exposure":[282],"9.3":[284],"\u00b1":[285,289],"4.1":[286],"9.4":[288],"3.9":[290],"However,":[293],"fewer":[297],"combination":[298,324],"treatments,":[299],"switches,":[300],"more":[302],"often":[303],"subsequent":[305],"line":[306],"other":[308,326],"CGRP":[309],"mAbs":[310],"cohort.":[314,338],"Conclusions":[315],"In":[316],"this":[317],"prospective":[318],"study,":[320],"less":[330],"frequent":[331],"There":[339],"larger":[342],"reduction":[343],"MHDs":[345],"requiring":[346],"initiating/switching":[351],"TOMP.":[356],"Trial":[357],"Registration":[358],"trial":[360],"registered":[362],"on":[363],"June":[364],"21,":[365],"2019,":[366],"European":[369],"Network":[370],"Centres":[372],"Pharmacoepidemiology":[374],"Pharmacovigilance":[376],"identifier":[379],"EUPAS33068.":[380]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-10-30T00:00:00"}